FDA plans ultra-fast review of three psychedelic drugs following Trump directive
Read full article: FDA plans ultra-fast review of three psychedelic drugs following Trump directiveThe Food and Drug Administration says it will offer ultra-fast review to three psychedelic drugs being studied for hard-to-treat mental health conditions, including depression.

:strip_exif(true):strip_icc(true):no_upscale(true):quality(65)/cloudfront-us-east-1.images.arcpublishing.com/gmg/MSA5G7OXONGTBILQTZHS4CWPDA.jpg)
:strip_exif(true):strip_icc(true):no_upscale(true):quality(65)/cloudfront-us-east-1.images.arcpublishing.com/gmg/XU7I5GWJJJDX3F4MS72BFNDZFU.jpg)
:strip_exif(true):strip_icc(true):no_upscale(true):quality(65)/cloudfront-us-east-1.images.arcpublishing.com/gmg/DP7LBXGWGVDZPCOFXBXIGGPJNU.jpg)
:strip_exif(true):strip_icc(true):no_upscale(true):quality(65)/cloudfront-us-east-1.images.arcpublishing.com/gmg/OCHMH3AVKFDSJL3XPXYYPNXJTU.jpg)
:strip_exif(true):strip_icc(true):no_upscale(true):quality(65)/cloudfront-us-east-1.images.arcpublishing.com/gmg/746LUMZ56FCH7O7U7NCKLXJX5A.jpg)